In a nutshell This study will investigate the effectiveness of daratumumab (Darzalex) added to VR-d regime [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Decadron)] versus VR-d alone in untreated multiple myeloma (MM). The development of minimal residual disease (MRD; a very small number of cancer cells remaining after treatment)...
Read MorePerformance status-2 – Symptomatic, 50 in bed Posts on Medivizor
Looking for patients with relapse/unresponsive lymphoma to test a treatment combination
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read MoreLooking for participants with colorectal cancer and liver metastasis to test a new cancer vaccine
In a nutshell This trial is examining the effectiveness of mFOLFOX6 (oxaliplatin, leucovorin, fluorouracil) and nivolumab (Opdivo) with and without a new cancer vaccine (CV301) for patients with colorectal cancer that has spread to the liver. The main outcome will be overall survival. This trial is being conducted in California and New Jersey,...
Read MoreEvaluating a new CAR-T cell therapy for patients with relapsed or refractory multiple myeloma
In a nutshell This study investigated the safety and effectiveness of a new chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study found that this cell therapy was effective, but it had significant side effects. Some background MM is a type of cancer of the...
Read MoreLooking for patients with relapsed or unresponsive mantle cell lymphoma to test a new treatment
In a nutshell This phase 2 trial is evaluating the safety and effectiveness of a new targeted therapy for relapsed or unresponsive mantle cell lymphoma (MCL). The main outcome to be measured is the overall response rate to treatment. The details Ibrutinib (Imbruvica) is a commonly used therapy for patients with relapsed or refractory MCL. This...
Read MoreStereotactic body radiation therapy in patients with inoperable lung cancer
In a nutshell This study wanted to find out how well a treatment for lung cancer called stereotactic body radiation therapy works in patients with lung cancer that cannot be surgically removed. The study found that this treatment is effective in patients with lung cancer, and a higher dose of radiation is not any better than a lower dose. Some...
Read MoreThe socioeconomic impact of cachexia in elderly patients with advanced lung cancer
In a nutshell This study looked at the impact of cachexia (weakness or wasting of the body) in elderly patients with advanced non-small-cell lung cancer on disability, hospitalization and medical costs. The authors concluded that patients with cachexia had a higher risk of disability, longer hospital stays and higher medical costs, while being treated...
Read MoreLooking for participants with chronic myeloid leukemia to receive axitinib and bosutinib
In a nutshell This phase 1 and 2 trial aims to determine the effectiveness and optimal dose of Axitinib and Bosutinib in patients with chronic myeloid leukemia. The outcome to be measured is the response to treatment based on genetic analysis and blood cell count, and the side effects. The study is located in Houston, Texas, United States. The...
Read MoreLooking for participants with relapsed and/or refractory multiple myeloma to receive ixazomib or pomalidomide
In a nutshell This study aims to compare ixazomib plus dexamethasone versus pomalidomide plus dexamethasone on survival in participants with relapse and/or refractory multiple myeloma. The outcome to be measured is the duration of time until disease progresses (worsens). The details Multiple myeloma is a cancer of the plasma cells in the...
Read MoreLooking for patients with newly diagnosed symptomatic NSCLC to test durvalumab
In a nutshell This phase 2 clinical trial will test the safety and effectiveness of durvalumab as a first-line therapy for non-small cell lung cancer (NSCLC). The primary outcome will be measured by overall survival and the number of patients with adverse (negative) side effects. The details Durvalumab is an immunotherapy for metastatic tumors...
Read MoreLooking for patients with relapsed/refractory multiple myeloma to test the safety and effectiveness of isatuximab
In a nutshell This phase 1 clinical trial will test the safety of isatuximab (SAR650984) in patients with relapsed or refractory multiple myeloma, as well as the effectiveness of isatuximab in multiple myeloma patients who have been previously treated with daratumumab (Darzalex). The primary outcome will be measured by side effects and overall...
Read MoreSearching for patients with high-risk smoldering multiple myeloma to test the effectiveness of an immunotherapy
In a nutshell This phase 2 clinical trial will test the effectiveness of isatuximab (SAR650984) in patients with high-risk smoldering multiple myeloma. The primary outcome will be measured by the overall response. This trial is being conducted at Mount Sinai Hospital and Memorial Sloan Kettering Cancer Center in New York, New York, as well as...
Read More
